A surgeon-performed saphenous nerve block from within the knee after it exits from the adductor canal at the time of total knee arthroplasty is feasible and may be a useful alternative to an ...

References: Pacira announces FDA approval of expanded Exparel label to include two additional nerve block indications. News release. Pacira BioSciences, Inc. November 10, 2023.

The adductor canal block preserves quadriceps strength and provides equivalent levels of postoperative analgesia for outpatient ACL surgery as the conventional femoral nerve block, according to a new ...

Study achieved primary and key secondary endpoints of statistically significant reductions in postsurgical pain and opioid consumption through 96 hoursTAMPA, Fla., Sept. 07, 2022 (GLOBE NEWSWIRE ...

BOSTON — Patients who undergo ACL reconstruction with an adductor canal nerve block have similar perioperative pain control and narcotic requirements compared to patients who receive femoral ...

A case is reported of chronic exertional compartment syndrome treated by fasciotomy. The decompression procedure was complicated by injury to the saphenous nerve. The importance of accurate placement ...

Pacira BioSciences announces positive topline data from phase 3 study of Exparel as a single-dose femoral nerve block in the adductor canal for total knee arthroplasty. News release.

Surgeons use an adductor canal block for anesthesia and analgesia to perform operations on the knee, medial lower leg, and ankle. A sciatic nerve block in the popliteal fossa is administered to ...

An adductor canal block is used for anesthesia and analgesia for surgery of the knee, medial lower leg, and ankle surgeries. A sciatic nerve block in the popliteal fossa is used for anesthesia and ...

Results showed the addition of a single-injection proximal sciatic nerve block to an adductor canal block significantly reduced pain and opioid requirements in pediatric patients undergoing medial ...

--Pacira BioSciences, Inc., the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced positive topline results from its Phase 3 study ...